Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
Recombinant immunotoxins (RITs) are genetically engineered proteins being developed to treat cancer. They are composed of an Fv that targets a cancer antigen and a portion of a protein toxin. Their clinical success is limited by their immunogenicity. Our goal is to produce a new RIT that targets mes...
Main Authors: | Mazor, Ronit, Onda, Masanori, Park, Dong, Addissie, Selamawit, Xiang, Laiman, Zhang, Jingli, Hassan, Raffit, Pastan, Ira |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058652/ |
Similar Items
-
Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
by: Hollevoet, Kevin, et al.
Published: (2015) -
Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P
by: Mattoo, Abid R., et al.
Published: (2013) -
Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
by: Zhang, Jingli, et al.
Published: (2014) -
Modulating Mesothelin Shedding to Improve Therapy
by: Zhang, Yujian, et al.
Published: (2012) -
Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
by: Leshem, Jasmin, et al.
Published: (2015)